Dominari Holdings, Inc.

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US0088753043
USD
4.19
0.01 (0.12%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

52 Week

Valuation
Technical
Day's Volume

CASH

64.03 k

Shareholding (Mar 2025)

FII

0.15%

Held by 5 FIIs

DII

97.68%

Held by 2 DIIs

Promoter

0.00%

How big is Dominari Holdings, Inc.?

22-Jun-2025

As of Jun 18, Dominari Holdings, Inc. has a market capitalization of 74.11 million and reported net sales of 24.88 million, with a net profit loss of 41.75 million over the latest four quarters. Shareholder's funds are at 39.85 million, and total assets are 48.01 million.

As of Jun 18, Dominari Holdings, Inc. has a market capitalization of 74.11 million, categorizing it as a Micro Cap company.<BR><BR>As of Jun 18, the company reported net sales of 24.88 million for the latest four quarters. However, it also experienced a net profit loss of 41.75 million during the same period.<BR><BR>As of Dec 24, the company's shareholder's funds stood at 39.85 million, while total assets were reported at 48.01 million.

Read More

What does Dominari Holdings, Inc. do?

22-Jun-2025

Dominari Holdings, Inc. is a biotechnology company focused on developing small-molecule anti-cancer therapeutics. As of March 2025, it reported net sales of $8 million and a net loss of $32 million, with a market cap of $74.11 million.

Overview:<BR>Dominari Holdings, Inc. is a biotechnology company focused on developing a diverse portfolio of small-molecule anti-cancer therapeutics within the Pharmaceuticals & Biotechnology industry.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 8 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -32 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 74.11 Million (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 2.37% <BR>Debt Equity: -0.44 <BR>Return on Equity: -83.25% <BR>Price to Book: 1.75<BR><BR>Contact Details:<BR>Address: ONE ROCKEFELLER PLAZA, 11TH FLOOR, NEW YORK NY: 10020 <BR>Tel: 1 347 3217646 <BR>Fax: 1 302 6745266 <BR>Website: http://www.spherix.com/

Read More

Should I buy, sell or hold Dominari Holdings, Inc.?

22-Jun-2025

Who are in the management team of Dominari Holdings, Inc.?

22-Jun-2025

As of March 2022, the management team of Dominari Holdings, Inc. includes Dr. Robert Vander Zanden (Independent Chairman), Mr. Anthony Hayes (CEO and multiple officer roles), and Directors Mr. Robert Dudley, Mr. Gregory Blattner, Mr. Tim Ledwick, and Mr. Paul LeMire. The team features a blend of executive leadership and independent directors.

As of March 2022, the management team of Dominari Holdings, Inc. includes the following individuals:<BR><BR>- Dr. Robert Vander Zanden, who serves as the Independent Chairman of the Board.<BR>- Mr. Anthony Hayes, who holds multiple roles as the Chief Executive Officer, Principal Financial Officer, Principal Accounting Officer, and Director.<BR>- Mr. Robert Dudley, who is a Director.<BR>- Mr. Gregory Blattner, who serves as an Independent Director.<BR>- Mr. Tim Ledwick, who is also an Independent Director.<BR>- Mr. Paul LeMire, who serves as an Independent Director.<BR><BR>This team comprises a mix of executive leadership and independent directors, contributing to the governance of the company.

Read More

Is Dominari Holdings, Inc. overvalued or undervalued?

20-Sep-2025

As of November 6, 2023, Dominari Holdings, Inc. is considered risky and overvalued due to poor financial metrics, including a Price to Book Value of 1.87 and a troubling ROCE of -169.94%, with its stock price of 6.33 significantly below its 52-week high of 13.58.

As of 6 November 2023, the valuation grade for Dominari Holdings, Inc. has moved from does not qualify to risky. The company appears to be overvalued given its financial metrics, particularly with a Price to Book Value of 1.87, an EV to Sales ratio of 2.45, and a troubling ROCE of -169.94%. In comparison to peers, Dominari's EV to EBITDA stands at -1.51, while Frequency Therapeutics, Inc. shows a slightly better EV to EBITDA of -1.0091, indicating that Dominari is lagging behind in operational efficiency.<BR><BR>The stock's current price of 6.33 is significantly below its 52-week high of 13.58, suggesting volatility and potential investor concerns. Although specific return data is not available, the lack of positive performance metrics reinforces the notion that Dominari Holdings is overvalued in the current market context.

Read More

Is Dominari Holdings, Inc. technically bullish or bearish?

20-Sep-2025

As of September 9, 2025, Dominari Holdings, Inc. shows a mildly bullish technical trend, supported by bullish daily moving averages and weekly MACD, but caution is advised due to a bearish monthly RSI.

As of 9 September 2025, the technical trend for Dominari Holdings, Inc. has changed from bullish to mildly bullish. The weekly MACD indicates a bullish stance, while the monthly MACD is mildly bullish. The daily moving averages are bullish, supporting a positive short-term outlook. However, the monthly RSI is bearish, suggesting potential weakness. The Bollinger Bands are mildly bullish on both weekly and monthly time frames, indicating some upward momentum. The KST shows a mixed signal with weekly mildly bearish and monthly bullish readings. Overall, the technical stance is mildly bullish, but with caution due to the bearish monthly RSI. Multi-period return data is not available for comparison with the S&P 500.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
1

With a growth in Net Sales of 452.24%, the company declared Very Positive results in Jun 25

  • OPERATING CASH FLOW(Y) Highest at USD -7.05 MM
  • ROCE(HY) Highest at -29.28%
  • RAW MATERIAL COST(Y) Fallen by -1.48% (YoY)
2

With ROE of -83.25%, it has a risky valuation with a 1.87 Price to Book Value

3

MFs have decreased holdings this quarter and now hold 2.17% of the company

 
4

Market Beating Performance

stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 94 Million (Micro Cap)

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

3.16%

stock-summary
Debt Equity

-0.32

stock-summary
Return on Equity

-62.05%

stock-summary
Price to Book

1.07

Revenue and Profits:
Net Sales:
34 Million
(Quarterly Results - Jun 2025)
Net Profit:
18 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-29.22%
0%
-29.22%
6 Months
-3.46%
0%
-3.46%
1 Year
145.03%
0%
145.03%
2 Years
84.99%
0%
84.99%
3 Years
18.36%
0%
18.36%
4 Years
-63.37%
0%
-63.37%
5 Years
-59.26%
0%
-59.26%

Dominari Holdings, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
121.90%
EBIT Growth (5y)
-237.61%
EBIT to Interest (avg)
-15.42
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.44
Sales to Capital Employed (avg)
0.26
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
6.07%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
1.87
EV to EBIT
-1.50
EV to EBITDA
-1.51
EV to Capital Employed
2.54
EV to Sales
2.45
PEG Ratio
NA
Dividend Yield
2.21%
ROCE (Latest)
-169.94%
ROE (Latest)
-83.25%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
No Trend
Mildly Bearish
OBV
No Trend
Mildly Bullish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 5 Schemes (2.17%)

Foreign Institutions

Held by 5 Foreign Institutions (0.15%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 450.00% vs 6,100.00% in Jun 2024",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 390.16% vs 29.89% in Jun 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "34.10",
          "val2": "6.20",
          "chgp": "450.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-19.20",
          "val2": "-2.60",
          "chgp": "-638.46%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "36.70",
          "val2": "-6.10",
          "chgp": "701.64%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "17.70",
          "val2": "-6.10",
          "chgp": "390.16%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-569.80%",
          "val2": "-443.10%",
          "chgp": "-12.67%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 805.00% vs 0.00% in Dec 2023",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 35.81% vs -3.62% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "18.10",
          "val2": "2.00",
          "chgp": "805.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-11.00",
          "val2": "-21.40",
          "chgp": "48.60%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-11.10",
          "val2": "-1.40",
          "chgp": "-692.86%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-14.70",
          "val2": "-22.90",
          "chgp": "35.81%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-635.20%",
          "val2": "-10,689.60%",
          "chgp": "1,005.44%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoYstock-summary
Jun'25
Jun'24
Change(%)
Net Sales
34.10
6.20
450.00%
Operating Profit (PBDIT) excl Other Income
-19.20
-2.60
-638.46%
Interest
0.00
0.00
Exceptional Items
36.70
-6.10
701.64%
Consolidate Net Profit
17.70
-6.10
390.16%
Operating Profit Margin (Excl OI)
-569.80%
-443.10%
-12.67%
USD in Million.
Direction Arrows
Net Sales

YoY Growth in quarter ended Jun 2025 is 450.00% vs 6,100.00% in Jun 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in quarter ended Jun 2025 is 390.16% vs 29.89% in Jun 2024

Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
18.10
2.00
805.00%
Operating Profit (PBDIT) excl Other Income
-11.00
-21.40
48.60%
Interest
0.00
0.00
Exceptional Items
-11.10
-1.40
-692.86%
Consolidate Net Profit
-14.70
-22.90
35.81%
Operating Profit Margin (Excl OI)
-635.20%
-10,689.60%
1,005.44%
USD in Million.
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2024 is 805.00% vs 0.00% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 35.81% vs -3.62% in Dec 2023

stock-summaryCompany CV
About Dominari Holdings, Inc. stock-summary
stock-summary
Dominari Holdings, Inc.
Pharmaceuticals & Biotechnology
Aikido Pharma Inc., formerly Spherix Incorporated, is a biotechnology company. The Company is focused on developing a diverse portfolio of small-molecule anti-cancer therapeutics. Its diverse pipeline of therapeutics includes therapies for pancreatic cancer, acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). In addition, the Company is constantly seeking to grow its pipeline to treat its unmet medical needs in oncology.
Company Coordinates stock-summary
Company Details
ONE ROCKEFELLER PLAZA, 11TH FLOOR , NEW YORK NY : 10020
stock-summary
Tel: 1 347 3217646
stock-summary
Registrar Details